Please use this identifier to cite or link to this item:
Title: Rasagiline delays retinal degeneration in a mouse model of retinitis pigmentosa via modulation of Bax/Bcl-2 expression.
Authors: Garcia-Delgado, Ana B
Valdés-Sánchez, Lourdes
Calado, Sofia M
Diaz-Corrales, Francisco J
Bhattacharya, Shom S
Keywords: Bax Bcl-2;neuroprotection;rasagiline;retinal degeneration;retinitis pigmentosa
metadata.dc.subject.mesh: Administration, Oral
Animals, Newborn
Disease Models, Animal
Disease Progression
Gene Expression
Mice, Transgenic
Neuroprotective Agents
Photoreceptor Cells
Proto-Oncogene Proteins c-bcl-2
Retinitis Pigmentosa
Vision, Ocular
bcl-2-Associated X Protein
Issue Date: 25-Jan-2018
Abstract: Retinitis pigmentosa (RP) is an inherited disease characterized by a progressive degeneration of rod photoreceptors. An imbalance between pro- and antiapoptotic factors, such as Bax/Bcl-2, has been involved in retinal degeneration. To date, no cure or effective treatments are available for RP. Rasagiline is an antiparkinsonian drug that has shown neuroprotective effects in part attributed to a modulation of Bax/Bcl-2 expression. In this study, we have evaluated the use of rasagiline as a potential treatment for RP. Newborn rd10 mice, a RP model, were treated with oral rasagiline during 30 days followed by a functional and morphological characterization of their mouse retinas. Treated animals showed a significant improvement in visual acuity and in the electrical responses of photoreceptors to light stimuli. Rasagiline delayed photoreceptor degeneration, which was confirmed not only by a high photoreceptor nuclei counting, but also by a sustained expression of photoreceptor-specific markers. In addition, the expression of proapoptotic Bax decreased, whereas the antiapoptotic factor Bcl-2 increased after rasagiline treatment. This study provides new evidences regarding the neuroprotective effect of rasagiline in the retina, and it brings new insight into the development of future clinical trials using this well-established antiparkinsonian drug to treat RP.
metadata.dc.identifier.doi: 10.1111/cns.12805
Appears in Collections:Producción 2020

Files in This Item:
There are no files associated with this item.

This item is protected by original copyright

Except where otherwise noted, Items on the Andalusian Health Repository site are licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives License.